Prioritizing local vaccine manufacturing in Africa is crucial to address health system challenges, including high burden diseases like malaria, TB, and HIV, as well as NCDs and emerging infectious diseases. The continent’s efforts to strengthen vaccine manufacturing capabilities, aligning with the PAVM framework, aim to reduce maternal and child mortality, prevent diseases like HPV and hepatitis B, and ensure equitable access to life-saving products. While progress has been made with operational companies in several African countries, further research and development efforts are needed to achieve self-reliance and address the reliance on global suppliers, aligning with milestones like the RTS, S/AS01 malaria vaccine and Lenacapavir for HIV prevention.
Full Article
Africa: Trump Attacks Global Minimum Tax
President Donald Trump's withdrawal from the OECD minimum 15% global tax deal could potentially harm Africa, impacting efforts to curb multinational tax avoidance practices that have led to significant financial losses on the continent. Trump's executive order threatens protective measures against foreign countries that tax US companies, raising concerns about sovereignty and retaliatory tax regimes. The OECD global tax deal aims to ensure large multinationals pay a minimum level of tax in all jurisdictions, potentially...
Read more
